Wall Street analysts forecast that TherapeuticsMD Inc (NASDAQ:TXMD) will announce earnings of ($0.22) per share for the current quarter, according to Zacks. Four analysts have made estimates for TherapeuticsMD’s earnings, with the highest EPS estimate coming in at ($0.15) and the lowest estimate coming in at ($0.31). TherapeuticsMD posted earnings of ($0.07) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 214.3%. The firm is expected to announce its next earnings report on Monday, November 5th.

On average, analysts expect that TherapeuticsMD will report full-year earnings of ($0.63) per share for the current fiscal year, with EPS estimates ranging from ($0.68) to ($0.58). For the next financial year, analysts expect that the company will report earnings of ($0.31) per share, with EPS estimates ranging from ($0.52) to ($0.08). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for TherapeuticsMD.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings data on Monday, July 30th. The company reported ($0.15) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.03). The firm had revenue of $3.80 million during the quarter, compared to the consensus estimate of $4.23 million. TherapeuticsMD had a negative net margin of 582.86% and a negative return on equity of 80.75%. The firm’s quarterly revenue was down 11.6% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.10) earnings per share.

A number of brokerages have commented on TXMD. BidaskClub upgraded TherapeuticsMD from a “strong sell” rating to a “sell” rating in a research report on Wednesday. Zacks Investment Research upgraded TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Saturday, August 25th. JPMorgan Chase & Co. set a $11.00 price objective on TherapeuticsMD and gave the company a “buy” rating in a research report on Wednesday, August 15th. ValuEngine upgraded TherapeuticsMD from a “hold” rating to a “buy” rating in a research report on Tuesday, May 8th. Finally, Oppenheimer set a $12.00 price objective on TherapeuticsMD and gave the company a “buy” rating in a research report on Tuesday, June 5th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have assigned a buy rating to the company. TherapeuticsMD has a consensus rating of “Buy” and an average price target of $14.00.

TXMD traded up $0.03 during mid-day trading on Friday, reaching $6.48. The stock had a trading volume of 24,318 shares, compared to its average volume of 2,695,546. The firm has a market capitalization of $1.44 billion, a price-to-earnings ratio of -17.51 and a beta of 1.53. The company has a debt-to-equity ratio of 0.94, a quick ratio of 7.79 and a current ratio of 7.88. TherapeuticsMD has a 52 week low of $4.34 and a 52 week high of $7.66.

Hedge funds have recently bought and sold shares of the company. Fox Run Management L.L.C. acquired a new position in shares of TherapeuticsMD in the 2nd quarter valued at $121,000. Affiance Financial LLC acquired a new position in shares of TherapeuticsMD in the 2nd quarter valued at $156,000. Beaumont Financial Partners LLC acquired a new position in shares of TherapeuticsMD in the 1st quarter valued at $123,000. Twin Focus Capital Partners LLC acquired a new position in shares of TherapeuticsMD in the 2nd quarter valued at $187,000. Finally, Xact Kapitalforvaltning AB lifted its stake in shares of TherapeuticsMD by 96.3% in the 1st quarter. Xact Kapitalforvaltning AB now owns 31,800 shares of the company’s stock valued at $155,000 after purchasing an additional 15,600 shares during the period. 66.14% of the stock is currently owned by institutional investors.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

Featured Story: Find a Trading Strategy That Works

Get a free copy of the Zacks research report on TherapeuticsMD (TXMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.